MARKET

OTLK

OTLK

Outlook Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.7800
-0.0450
-5.45%
Pre Market: 0.7689 -0.0111 -1.42% 08:07 02/27 EST
OPEN
0.7900
PREV CLOSE
0.8250
HIGH
0.8199
LOW
0.7200
VOLUME
587.37K
TURNOVER
--
52 WEEK HIGH
9.20
52 WEEK LOW
0.5200
MARKET CAP
20.08M
P/E (TTM)
-0.3614
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of OTLK and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average OTLK stock price target is 7.13 with a high estimate of 11.00 and a low estimate of 3.500.

EPS

OTLK News

More
  • Outlook Therapeutics Announces Closing of $10.2 Million Financings Priced At-The-Market
  • GlobeNewswire · 17h ago
  • SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Outlook Therapeutics, Inc.-OTLK
  • ACCESSWIRE · 1d ago
  • Outlook Therapeutics Conducts $10.2M Offering at $1.016/Share
  • Benzinga · 3d ago
  • Outlook Therapeutics Announces $10.2M Financings Priced At-The-Market
  • Benzinga · 3d ago

Industry

Biotechnology & Medical Research
+1.71%
Pharmaceuticals & Medical Research
+0.42%

Hot Stocks

Symbol
Price
%Change
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%

About OTLK

Outlook Therapeutics, Inc., formerly Oncobiologics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing, manufacturing and commercializing biosimilar therapeutics. It is focused on monoclonal antibodies (mAbs) in the disease areas of immunology and oncology. The Company offers BioSymphony Platform. The Company has identified approximately eight biosimilar product candidates, of which two product candidates are ONS-3010 and ONS-1045. ONS-3010 is an adalimumab (Humira) biosimilar. The Company has initiated Phase III preparatory activities for ONS-3010. Its second product candidate, ONS-1045, is a bevacizumab (Avastin) biosimilar. The Company's other preclinical product candidate, ONS-1050, a trastuzumab (Herceptin) biosimilar, interferes with the human epidermal growth factor receptor 2 (HER2). ONS-4010 is a biosimilar to denosumab (Prolia/Xgeva), which is a human mAb. Its other biosimilar product, ONS-1055, is a biosimilar to cetuximab.
More

Webull offers kinds of Outlook Therapeutics Inc stock information, including NASDAQ:OTLK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OTLK stock news, and many more online research tools to help you make informed decisions.